Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday

Enliven Therapeutics (NASDAQ:ELVN) is expected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Enliven Therapeutics to post earnings of ($0.42) per share and revenue of $0.0080 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $29.98 on Thursday. The company has a market capitalization of $1.78 billion, a P/E ratio of -16.12 and a beta of 0.33. The company has a 50 day simple moving average of $24.80 and a 200-day simple moving average of $21.74. Enliven Therapeutics has a 1 year low of $13.30 and a 1 year high of $30.63.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on ELVN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Insider Activity

In related news, Director Richard A. Heyman sold 9,635 shares of the company’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the sale, the director directly owned 25,545 shares of the company’s stock, valued at $639,391.35. This represents a 27.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the transaction, the chief operating officer owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. This trade represents a 18.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 233,843 shares of company stock valued at $6,145,489. 25.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after buying an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after buying an additional 80,506 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth about $578,000. Legal & General Group Plc increased its holdings in shares of Enliven Therapeutics by 52.2% in the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock valued at $646,000 after acquiring an additional 11,058 shares during the last quarter. Finally, Quantbot Technologies LP increased its holdings in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after acquiring an additional 1,434 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.